Clinical trials: Dermatomyositis, Adult Type
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood
Fitness Integrative Training for Pediatric Rheumatology Disorders
This study evaluates the feasibility of the Fitness Integrative Training program for Teens (FIT Teens 2), a combined cognitive behavioral therapy and neuromuscular exercise training program in patients with pediatric rheumatic…
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood, Joint Hypermobility, Juvenile Dermatomyositis
- Trial name
- FIT Teens 2 (NCT06556992)
- Testing
- FIT Teens
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Gastric Mucosal Manifestations in Patients With Dermatomyositis
Gastric Mucosal Changes in Patients With Dermatomyositis
There are a large number of reports in the literature that patients with dermatomyositis often have various malignant tumors, and reports of gastric cancer are not rare.
- Trial name
- NCT05402670
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Interstitial Lung Disease, Scleroderma
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Inflammatory Myositis, Mixed Connective Tissue Disease
- Trial name
- RECITAL (NCT01862926)
- Testing
- Rituximab, Cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Dermatomyositis
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis.
- Trial name
- NCT06857240
- Testing
- Ruxolitinib Topical Cream
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Dermatomyositis
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine.
- Trial name
- NCT02466243
- Testing
- JBT-101
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Dermatomyositis
Study of NM8074 in Patients with Dermatomyositis (DM)
This is a Phase II, open-label, multicenter study to evaluate the safety and efficacy of NM8074 administered via intravenous infusion in patients with Dermatomyositis (DM).
- Trial name
- NCT06887738
- Testing
- NM8074
- Volunteers
- 8 people
- Sponsor
- NovelMed Therapeutics
Myositis, Dermatomyositis
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Rituximab is a man-made antibody used to treat certain types of cancer. This study will determine whether rituximab is an effective treatment for adult and pediatric patients with dermatomyositis or polymyositis.
- Conditions
- Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
- Trial name
- NCT00106184
- Testing
- Rituximab
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Dermatomyositis, Respiratory Injury
Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis
Dermatomyositis (DM) is a highly heterogeneous autoimmune disease characterized by rash and myasthenia. Beside these, respiratory involvement is one of the common complications of DM.
- Trial name
- CRAWFORD (NCT04747652)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
To evaluate the safety and tolerability of escalating, single subcutaneous doses of MEDI7734 in adult subjects with type I interferon-mediated autoimmune diseases.
- Trial name
- NCT02780674
- Testing
- MEDI7734
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Amgen
Active Dermatomyositis
Safety and Efficacy of BAF312 in Dermatomyositis
This study investigated the dose response relationship for the efficacy and safety of BAF312 compared to placebo in active DM patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal…
- Trial name
- NCT02029274
- Testing
- BAF312
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Dermatomyositis, Polymyositis
Adult and Juvenile Myositis
This study will evaluate subjects with adult- and childhood-onset myositis to learn more about their cause and the immune system changes and medical problems associated with them.
- Conditions
- Dermatomyositis, Polymyositis, Inclusion Body Myositis
- Trial name
- NCT00017914
- Where
- 4 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Clinically Amyopathic Dermatomyisitis(CAMD)
Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease
Acute respiratory distress syndrome (ARDS) occurs in Clinically Amyopathic Dermatomyisitis(CADM) combined with Rapidly Progressive Interstitial Lung Disease(RPILD) within 1-3 months, which leads to death of patients and is…
- Trial name
- NCT04613219
- Testing
- Tofacitinib 5 MG [Xeljanz]
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jing Liang
Systemic Lupus, Rheumatoid Arthritis
Yellow Fever Vaccine in Patients With Rheumatic Diseases
According to World Health Organization (WHO), since December 2016, Brazil is showing a significant increase in cases of yellow fever in humans.
- Conditions
- Systemic Lupus, Rheumatoid Arthritis, Spondyloarthritis, Inflammatory Myopathy
- Trial name
- NCT03430388
- Testing
- Yellow Fever vaccine (17D)
- Where
- Brazil
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Dermatomyositis
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants…
- Trial name
- NCT04999020
- Testing
- Ravulizumab
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 38 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myositis, Dermatomyositis
High-intensity Strength Training in Myositis
This study evaluates the effects of a high-intensity strength training in patients with myositis with the primary outcome being quality of life (SF-36).
- Conditions
- Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy
- Trial name
- HI-STIM (NCT04486261)
- Testing
- High-intensity strength training
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Dermatomyositis
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
The Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), established in 2008, is a one-site database study conducted at the University of Pennsylvania.
- Trial name
- CDASI (NCT02945345)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Pennsylvania
Myositis
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM).
- Trial name
- NCT05895786
- Testing
- PF-06823859
- Where
- 138 sites in United States, Argentina and 18 more
- Volunteers
- 318 people
- Sponsor
- Pfizer
Dermatomyositis
Interleukin-2 on Active Dermatomyositis
The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.
- Trial name
- NCT05495321
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University People's Hospital